Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses. Selective blockade of IL-23p19 with guselkumab was superior to blockade of TNF-α with adalimumab (ADA)...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-09-01
Saila:	JID Innovations
Gaiak:	Adalimumab Biomarkers Guselkumab IL-23/IL-17 pathway Psoriasis
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2667026724000341
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!